Precision Motion

Precision Motion (Opal V2C) is Clario's wearable biosensor solution designed for measuring objective digital endpoints of mobility in clinical trials. It supports both in-clinic and at-home data capture, enabling sponsors to quantify outcomes related to gait, balance, and additional mobility tests. The system is intended for use in trials across a range of neurological and movement-related indications.

The Opal V2C has been validated across multiple indications including Parkinson's Disease, Multiple Sclerosis, and Spinocerebellar Ataxia. Over the past decade, more than 1,000 researchers worldwide have used Opal technology, and the system has been cited in over 700 peer-reviewed scientific publications, with the broader body of evidence accumulating more than 45,000 scientific citations.

Core Measurement Domains

• Gait: Supports 2-minute walk, 6-minute walk, and open-ended walk assessments. Gait initiation and turns are included in the 2-minute walk and open-ended walk; turns are included in the 6-minute walk.
• Balance: Covers eyes open and closed conditions, feet apart and together positions, firm and foam surfaces, and tandem and single leg stances.
• Additional Mobility: Includes timed up and go, sit to stand, 360-degree turn, and stand and walk tests.
• Actigraphy: Captures activity and sleep data to provide real-world information about patient behaviour outside of formal assessments.

Key Capabilities

• Delivers real-time data through Precision Motion Monitoring (PerfO) covering gait, balance, and mobility.
• Includes pre-configured standard assessments with instrumented tests embedded in software, supporting more than 140 validated outcome measures.
• Provides analytics through the Mobility Lab software platform.
• Offers guided patient coaching throughout the assessment procedure to support consistent data collection.

Evidence and Publications

• Opal technology has been studied and cited in over 700 peer-reviewed scientific publications covering both technical and clinical applications.
• Related published research includes studies on wearable sensor-based gait and balance assessment in Alzheimer's Disease and Mild Cognitive Impairment, as well as studies identifying gait measures that discriminate Multiple Sclerosis from healthy control subjects.
• Clario maintains a searchable knowledge base of scientific publications associated with the Opal system.

A related product, the Opal V2R, is available as a research-grade wearable sensor for non-clinical research applications. The Opal V2C clinical trial solution is supported by Clario's expert scientific advisory team and is accessible through direct engagement with Clario's precision motion specialists.